Jianmin Mao, Ph.D.

Senior Vice President, CMC

Jianmin brings over 20 years of industrial experience in drug discovery and development. Most recently to Volastra, as Vice President of CMC at Beyond Spring Pharmaceuticals, he led the CMC team in Plinabulin NDA filings in the US and China. He has been instrumental in advancing multiple programs from preclinical through clinical development and through commercialization in various roles at prior companies which included Zikani Therapeutics (now Eloxx Pharmaceuticals), Flatley Discovery Lab, Melinta Therapeutics and ArQule Inc (now part of Merck). Jianmin received his B.S. and Ph.D. in organic chemistry from Lanzhou University. He is an author of more than 30 peer-reviewed publications and is an inventor on 12 issued patents.